

**DEPARTMENT OF SOCIAL AND HEALTH SERVICES
MEDICAL ASSISTANCE ADMINISTRATION
Olympia, Washington**

To: Pharmacists
All Prescribers
Managed Care Plans
Regional Administrators
CSO Administrators

Memorandum No. 00-53 MAA
Issued: June 15, 2000

For further information, call:
1-800-562-6188

From: James C. Wilson, Assistant Secretary
Medical Assistance Administration

Subject: Prescription Drug Program - Updates

This numbered memorandum describes:

- Additional drugs that must be billed first to Medicare for dual-eligible (Medicaid/Medicare Part B) clients; and
- Changes to the Medical Assistance Administration's (MAA) expedited prior authorization (EPA) criteria for proton pump inhibitors.

Additional Drugs That Must Be Billed To Medicare First

Effective the week of July 17, 2000, MAA will require that claims for the oral chemotherapy drugs listed below be billed to Medicare as the primary payor for clients eligible for both Medicare and Medical Assistance (dual-eligible):

- Capecitabine 150 mg tablets
- Cyclophosphamide 25 mg and 50 mg tablets
- Etoposide 50 mg capsules
- Melphalan 2 mg tablets

These are added to the list of drugs (inhalant solutions for nebulizers) that currently require billing to Medicare as the primary payor for dual-eligible clients.

See back for more information ➡

Changes to the EPA Criteria for Proton Pump Inhibitors

Effective the week of July 17, 2000, MAA will deny claims submitted for more than once daily dosing of proton pump inhibitors for the following EPA codes:

<u>EPA Code</u>	<u>Indication</u>
082	Short term treatment of active duodenal or gastric ulcer. Treatment limited to 4-8 weeks per episode - not as maintenance.
083	Acute Gastro Esophageal Reflux Disease (GERD) limited to 4-12 weeks.
085	First-line therapy for erosive esophagitis (4-12 weeks) or maintenance of healing of erosive esophagitis.
114	Medically indicated need for GERD maintenance.
115	Maintenance of healed duodenal ulcers.
126	Diagnosis of hiatal hernia when H2 blockers have been tried/failed.

MAA will continue to reimburse for twice daily dosing for the following EPA codes:

<u>EPA Code</u>	<u>Indication</u>
084	Pathological Hypersecretory Condition (PHC).
086	One part of a multiple dose regimen for the treatment of H. pylori infection.

All instructions contained in MAA's <u>Prescription Drug Program</u> Billing Instructions, dated December 1998 pertaining to Medicaid/Medicare billing and Expedited Prior Authorization continue to be applicable .
--

